<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2194">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03078322</url>
  </required_header>
  <id_info>
    <org_study_id>VSG-CL 003</org_study_id>
    <nct_id>NCT03078322</nct_id>
  </id_info>
  <brief_title>AV-101 as Adjunct Antidepressant Therapy in Patients With Major Depression</brief_title>
  <official_title>Double-Blind, Placebo-Controlled, Phase 2 Trial to Test Efficacy and Safety of AV-101 (L‑4‑Chlorokynurenine) as Adjunct to Current Antidepressant Therapy in Patients With Major Depressive Disorder (MDD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VistaGen Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VistaGen Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the safety and efficacy of AV-101.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2017</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Montgomery Åsberg Depression Rating Scale 6-item version (MADRS-6)</measure>
    <time_frame>2 weeks</time_frame>
    <description>Subset of MADRS total score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time course of improvement including response rates</measure>
    <time_frame>2 weeks</time_frame>
    <description>50% improvement on MADRS-10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability will be assessed by incidence of adverse events (AEs)</measure>
    <time_frame>2 weeks</time_frame>
    <description>Also include EKG, labs etc.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>AV-101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>L-4-chlorokynurenine 1440 mg daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AV-101</intervention_name>
    <description>1440 mg</description>
    <arm_group_label>AV-101</arm_group_label>
    <other_name>L-4-chlorokynurenine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with MDD, single or recurrent, and currently experiencing a MDE of at least
             8 weeks in duration.

          -  Has a history of inadequate response to at least 1 approved antidepressant including
             at least 1 and no more than 3 during the current depressive episode.

          -  Meet the threshold on the total HAMD-17 score of &gt; 20

          -  If female, a status of nonchildbearing potential or use of an acceptable form of
             birth control.

          -  Body mass index between 18 to 40 kg/m2.

          -  Other criteria may apply

        Exclusion Criteria:

          -  Current diagnosis of Axis I disorders other than persistent depressive disorder,
             agoraphobia, generalized anxiety disorder, social anxiety disorder, panic disorder,
             post-traumatic stress disorder, attention deficit disorder, complicated grief, binge
             eating disorder, obsessive compulsive disorder of mild severity, other specified
             anxiety disorder, or specific phobia unless one of these is clinically unstable.
             (Note: MDD must be the primary diagnosis).

          -  History of bipolar disorder, schizophrenia or schizoaffective disorders, or any
             history of psychotic symptoms in the current or previous depressive episodes.

          -  History of anorexia nervosa, bulimia nervosa, or other specified feeding or eating
             disorder, within 5 years of screening.

          -  Women who are pregnant or breastfeeding or a positive pregnancy test at screening or
             baseline.

          -  Currently taking a prohibited adjunct therapy. Such drugs must be washed out for at
             least 4 weeks prior to baseline.

          -  Current diagnosis of moderate or severe substance use (including alcohol) disorder
             (abuse or dependence, as defined by DSM-5), with the exception of nicotine
             dependence, at screening or within 6 months prior to screening.

          -  In the opinion of the investigator, the subject has a significant risk for suicidal
             behavior

          -  Has received electroconvulsive therapy, or had repetitive transcranial magnetic
             stimulation in the current episode.

          -  Has received vagus nerve stimulation at any time prior to screening.

          -  Any current or past history of any physical condition, which in the investigator's
             opinion might put the subject at risk or interfere with study results interpretation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 10, 2017</lastchanged_date>
  <firstreceived_date>March 8, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antidepressive Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
